Biomea Fusion (BMEA) Accumulated Expenses (2020 - 2026)
Biomea Fusion (BMEA) posted Accumulated Expenses of $3.4 million for Q1 2026, down 46.28% sequentially from $6.4 million in Q4 2025, and down 67.78% YoY from $10.7 million in Q1 2025.
Biomea Fusion (BMEA) Accumulated Expenses (2020 - 2026) Analysis & Trends
Biomea Fusion has reported Accumulated Expenses for 7 years, with the latest figure at $3.4 million in Q1 2026.
- Quarterly Accumulated Expenses fell 67.78% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (down 67.78% YoY) and the FY2025 annual result came in at $6.4 million, down 3.83% from the prior year.
- Accumulated Expenses eased to $3.4 million in Q1 2026 per BMEA's latest filing, from $6.4 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $17.4 million in Q1 2024 and troughed at $1.2 million in Q1 2022.
- A 5-year average of $8.1 million and a median of $6.7 million in 2024 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2025: Accumulated Expenses jumped 870.35% in 2024, then slumped 81.51% in 2025.
- Over 5 years, Accumulated Expenses stood at $11.7 million in 2022, then tumbled by 48.91% to $6.0 million in 2023, then gained by 11.85% to $6.7 million in 2024, then declined by 3.83% to $6.4 million in 2025, then sank by 46.28% to $3.4 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $3.4 million, $6.4 million, and $2.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Biomea Fusion | 97.69 Mn | 97.69 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.30 Mn |
| Mar 31, 2026 | 3.44 Mn |
| Dec 31, 2025 | 6.41 Mn |
| Sep 30, 2025 | 2.94 Mn |
| Jun 30, 2025 | 8.44 Mn |
| Mar 31, 2025 | 10.68 Mn |
| Dec 31, 2024 | 6.66 Mn |
| Sep 30, 2024 | 15.89 Mn |
| Jun 30, 2024 | 16.05 Mn |
| Mar 31, 2024 | 17.38 Mn |
| Dec 31, 2023 | 5.96 Mn |
| Sep 30, 2023 | 4.75 Mn |
| Jun 30, 2023 | 7.49 Mn |
| Mar 31, 2023 | 1.79 Mn |
| Dec 31, 2022 | 11.66 Mn |
| Sep 30, 2022 | 10.39 Mn |
| Jun 30, 2022 | 6.36 Mn |
| Mar 31, 2022 | 1.22 Mn |
| Dec 31, 2021 | 2.74 Mn |
| Sep 30, 2021 | 3.84 Mn |